<DOC>
	<DOCNO>NCT02974361</DOCNO>
	<brief_summary>This study help development new version Ibuprofen , call Ibuprofen-LDH . Ibuprofen-LDH use treatment muscular pain , headache , fever etc . This new version ibuprofen expect produce few stomach/intestine relate side effect compare many exist marketed formulation Ibuprofen . This study split 3 part . Part A 7 way crossover , Part B maximum 6 way crossover Part C maximum 4 way crossover . The size Parts B &amp; Part C allocate intervention confirm review data Parts A and/or B respectively . A total 30 subject take part study ; 10 per study part . The key objective ass pharmacokinetics property Ibuprofen-LDH , without selection different excipients . The pharmacokinetic property include quickly drug absorb bloodstream also maximum concentration drug reach bloodstream .</brief_summary>
	<brief_title>Impact Excipients Pharmacokinetics OXPzero ( TM ) Ibuprofen</brief_title>
	<detailed_description />
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Healthy male female subject BMI 18 30 kg/m2 Willing able provide write informed consent Evidence history significant renal , hepatic , gastrointestinal , central nervous system , respiratory , cardiovascular , autoimmune metabolic dysfunction Recent concurrent use prescription nonprescription medication , contraceptive Allergy sensitivity NSAIDs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>